CUE - Cue Biopharma, Inc. - SEC Form 4 Insider Trading Screener
19 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2018-12-24 | CUE | Digiandomenico Anthony | Dir | P - Purchase | $4.81 | +10,000 | 30,000 | +50% | +$48,100 | ||||||
2018-12-31 | CUE | Marlett Christopher A | Dir | P - Purchase | $4.64 | +18,521 | 1,116,575 | +2% | +$85,937 | ||||||
2018-12-28 | CUE | Digiandomenico Anthony | Dir | P - Purchase | $4.62 | +7,000 | 57,000 | +14% | +$32,340 | ||||||
2018-12-27 | CUE | Digiandomenico Anthony | Dir | P - Purchase | $4.77 | +20,000 | 50,000 | +67% | +$95,400 | ||||||
2018-12-26 | CUE | Marlett Christopher A | Dir | P - Purchase | $4.29 | +19,647 | 1,098,054 | +2% | +$84,286 | ||||||
2018-12-21 | CUE | Suri Anish | Chief Scientific Officer | P - Purchase | $4.37 | +2,000 | 2,000 | New | +$8,740 | ||||||
2018-12-21 | CUE | Marlett Christopher A | Dir | P - Purchase | $4.53 | +17,200 | 1,078,407 | +2% | +$77,916 | ||||||
2018-12-21 | CUE | Digiandomenico Anthony | Dir | P - Purchase | $4.49 | +10,000 | 20,000 | +100% | +$44,900 | ||||||
2018-12-20 | CUE | Marlett Christopher A | Dir | P - Purchase | $4.74 | +9,438 | 1,061,207 | +1% | +$44,736 | ||||||
2018-12-19 | CUE | Marlett Christopher A | Dir | P - Purchase | $5.00 | +400 | 1,051,769 | 0% | +$2,000 | ||||||
2018-12-18 | CUE | Marlett Christopher A | Dir | P - Purchase | $5.20 | +3,664 | 1,051,369 | 0% | +$19,053 | ||||||
2018-12-17 | CUE | Digiandomenico Anthony | Dir | P - Purchase | $5.48 | +10,000 | 10,000 | New | +$54,800 | ||||||
2018-12-13 | CUE | Marlett Christopher A | Dir | P - Purchase | $5.06 | +10,000 | 1,047,705 | +1% | +$50,600 | ||||||
2018-12-12 | CUE | Marlett Christopher A | Dir | P - Purchase | $5.08 | +12,189 | 1,037,705 | +1% | +$61,978 | ||||||
2018-12-11 | CUE | Marlett Christopher A | Dir | P - Purchase | $4.86 | +7,543 | 1,025,516 | +1% | +$36,659 | ||||||
2018-08-29 | CUE | Millar Kerri-Ann | VP-Finance | P - Purchase | $8.48 | +1,000 | 1,000 | New | +$8,480 | ||||||
2018-08-16 | CUE | Passeri Daniel R | CEO, Pres | P - Purchase | $8.09 | +6,000 | 47,600 | +14% | +$48,510 | ||||||
2018-06-29 | CUE | Passeri Daniel R | CEO, Pres | P - Purchase | $11.97 | +1,600 | 41,600 | +4% | +$19,152 | ||||||
2017-12-27 | CUE | Pienta Kenneth | Chief Medical Officer | P - Purchase | $7.50 | +2,000 | 2,000 | New | +$15,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |